News


August 24th, 2020

Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors

VANCOUVER, British Columbia — Aug-24-2020 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that Karn Manhas, Founder and CEO of Terramera and agtech industry pioneer, has joined Qu Biologics’ Board of Directors. Karn Manhas, […]

READ MORE >
August 18th, 2020

Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer

Vancouver, British Columbia – August-18-2020 (GlobalNews Wire) – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial of QBECO SSI in patients with colorectal cancer. […]

READ MORE >
April 4th, 2020

Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection

VANCOUVER, British Columbia – Apr-6-2020 (GLOBE NEWSWIRE) – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore the body’s innate immune system, has published for the first time the basis of their first-in class therapy. The series of studies, published this week in […]

READ MORE >
December 19th, 2019

Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease

VANCOUVER, British Columbia – Dec. 18, 2019 (GLOBE NEWSWIRE) — Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce the completion of enrollment for the first stage of the RESTORE clinical trial, “A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled […]

READ MORE >
July 23rd, 2019

Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease

Vancouver, British Columbia – July 23rd, 2019 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore the body’s innate immune system, is pleased to report that the results of their first randomized-placebo controlled trial (RCT) in patients with moderate-to-severe Crohn’s disease (CD) […]

READ MORE >
July 25th, 2018

Qu Biologics enrolls the first patient in new Phase 2 Crohn’s disease clinical trial

Vancouver, British Columbia – July 25, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the  RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease has been […]

READ MORE >
July 9th, 2018

Crohn’s disease clinical trial – Now enrolling

Qu Biologics is now recruiting Canadian residents to participate in the first stage of a Phase 2 clinical trial of QBECO SSI in the treatment of adults living with moderate to severe Crohn’s disease. The aim of this trial is to further establish the safety and efficacy of the investigational drug QBECO SSI for the […]

READ MORE >
May 16th, 2018

Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board

Vancouver, British Columbia – May 15th, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce the addition of four members to Qu’s Scientific Advisory Board (SAB), consisting of world leading experts in the fields of innate […]

READ MORE >
May 10th, 2018

Qu Biologics SSIs featured in Inside Tract magazine

Qu Biologics’ paradigm shifting approach to IBD is featured in the March April 2018 issue of the Gastrointestinal Society’s ‘Inside Tract’ magazine. Read the full article here

READ MORE >
April 20th, 2018

Qu Biologics begins Phase 2 Clinical Trial in Crohn’s disease

Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore innate immune function, is pleased to announce the receipt of a ‘No Objection Letter’ (NOL) from Health Canada and the initiation of their follow-on Phase 2 clinical trial to study QBECO SSI for […]

READ MORE >

Past events:


Past events: